Radiopharmaceutical · Kills target cells, directed at fibroblast activation protein (FAP) · developed by ELI LILLY &
Lutetium Lu 177-labeled FAP-targeting ligand LY4337713 is a radioconjugate that binds fibroblast activation protein (FAP), a cell surface protein overexpressed on cancer-associated fibroblasts in the tumor microenvironment. It delivers beta radiation from lutetium Lu 177 to these fibroblasts. It is being studied in advanced solid tumors, including ovarian, breast, pancreatic, colorectal, esophageal, gastric and biliary cancers.
Summary written with AI from the sources listed at the end of this page.
Advanced Solid TumorsBreast NeoplasmsCholangiocarcinomaColorectal NeoplasmsEsophageal NeoplasmsOvarian NeoplasmsPancreatic Intraductal NeoplasmsStomach Neoplasms
See LLY's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
LLY catalysts and pipeline →